A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined with ART Initiation during Acute HIV Infection to Induce HIV Remission
To find out if bNAbs, VRC07-523LS and PGT121.414.LS, are safe for administration with ART. To evaluate if the bNAbs are effective at keeping HIV from reproducing. It is necessary to stop taking ART after receiving the bNAbs or placebos for bNAbs. This is
Why this Research Matters
Scientists are looking for ways to minimize the distribution of HIV-1 in the body, especially where anti-HIV medications (ART) are unable to reach. Starting ART as soon as possible following a diagnosis of Acute HIV Infection (AHI) has been shown to better
Who can Participate
Documentation of recently confirmed HIV-1 (acute infection). Be between 18 and 70 years old. Be willing to take broadly neutralizing antibodies and start treatment for HIV. Not have taken pre-exposure ART (PrEP) within the past 60 days. No active hepat
Study ID
Protocol Number: 23-0252
More information available at ClinicalTrials.gov: NCT05719441
Meet the Team
Principal Investigator